Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
When planning prostate brachytherapy, do you use a bladder neck constraint?
If so, what dose constraint do you follow and how do you contour the bladder neck?
Answer from: Radiation Oncologist at Community Practice
With real time planning, try to limit it to 85 percent of the prescription dose. Smith et al., PMID 20888139
Sign in or Register to read more
14564
Related Questions
Would you treat a patient with evidence of prostate cancer who refuses biopsy?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
Is there evidence that prostatectomy improves overall survival in local recurrence of prostate cancer post-definitive radiation?
How long would you delay prostate radiation following use of a paclitaxel-eluting balloon dilator (optilume) for management of a recurrent urethral stricture after TURP?
Would you offer palliative radiation to a patient with hematuria from squamous metaplasia of the bladder that is not responding to endoscopic therapy?
How would you treat a newly diagnosed hormone sensitive high risk prostate cancer with one small lung metastasis and no other evidence of metastatic disease per PSMA PET?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
What are the indications for postoperative radiation for extramammary Paget's disease?
What adjuvant treatment would you offer a patient who underwent cystoprostatectomy for a muscle invasive bladder cancer and discovered to also have prostate cancer?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?